Skip to content
OmniaBio Full Color Logo

Learn more about our CDMO facilities

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
  • Contact
OmniaBio Full Color Logo

Learn more about our CDMO facilities

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
  • Contact

Webinar

BROWSE ALL
December 20, 2024
|
Webinar

Enhancing Lentiviral Vector Stability and Recovery: Optimizing Buffer Formulation

Lentiviral vectors (LVV) are critical tools in both in vivo gene therapy and ex vivo cell therapy manufacturing and have been extensively used for investigational and commercial purposes. Despite existing buffer formulations, there are significant opportunities to develop more robust LVV formulation buffer systems that improve stability and consequently increase recovery of infectious viruses.

In this webinar, we will delve into a detailed case study showcasing our work conducting design of experiments (DoE) to optimize LVV stability:

  • Learn how DoE can be utilized to optimize buffer formulations that enhance LVV stability
  • Understand key factors affecting LVV stability, including buffer composition, additives, and virus concentration
  • Explore testing conditions for analyzing short-term and long-term LVV stability

 

Related Content
Loading...
CAR-T Manufacturing Intensification Webinar Transcript
Webinar
Webinar Transcript: CAR-T Manufacturing Intensification: The Next Wave of CAR-T Commercialization
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
Podcast thumbnail
Webinar
Driving Innovation in Cell and Gene Therapy: The Role of AI and Robotics
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
Podcast
Webinar
From Promise to Practice – AI’s Impact on Cell and Gene Therapy Development
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
Podcast
Webinar
Biomanufacturing Redefined: The Role of AI and Robotics in Producing Cell and Gene Therapies
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
CAR-T-Tech-Transfer-Webinar
Webinar
Unlocking Success in CAR-T Technology Transfer: From Challenges to Seamless Execution
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
On demand PDF webinar transcript
Webinar
Webinar Transcript: iPSC-based Therapy Dilemmas Explored: Overcoming Hurdles for Future Success
DOWNLOAD NOW
DOWNLOAD NOW
WATCH NOW
1 2 Next »
OmniaBio Footer Logo in Full Color

© 2025 OmniaBio   |   Privacy Policy

  • Expertise
    • Cell & Gene Therapy Expertise
    • Immunotherapy
    • LVV
    • iPSC
  • Services
    • Cell & Gene Therapy Services Overview
    • Process Development
    • Analytical Development
    • Commercial Manufacturing
    • GMP Manufacturing
    • Autologous Cell Therapy Manufacturing
    • Cell Banking
    • Regulatory Guidance
    • Supply Chain Security
  • About
    • Overview
    • Facilities
    • Leadership
    • Careers
  • Resource Centre
    • Posters
    • Blog
    • Webinars
    • Videos
  • Media & Events
    • Press Releases
    • OmniaBio in the News
    • Events
Contact Us
Scroll to Top